[HTML][HTML] Clinical and biological evaluation of the novel CD30/CD16A tetravalent bispecific antibody (AFM13) in relapsed or refractory CD30-positive lymphoma with …
A Sawas, PH Chen, M Lipschitz, S Rodig, G Vlad - Blood, 2020 - Elsevier
… AFM13 is a CD30/CD16A targeting high affinity bispecific tetravalent antibody that engages
and … innate cell engager AFM13 is a CD30/CD16A targeting high affinity bispecific tetravalent …
and … innate cell engager AFM13 is a CD30/CD16A targeting high affinity bispecific tetravalent …
[HTML][HTML] Clinical and biological evaluation of the novel CD30/CD16A tetravalent bispecific antibody (AFM13) in relapsed or refractory CD30-positive lymphoma with …
A Sawas, H Elgedawe, G Vlad, M Lipschitz, PH Chen… - Blood, 2018 - Elsevier
… AFM13 is a CD30/CD16A targeting high affinity bispecific tetravalent antibody that engages
and activates NK cells. This study evaluates the ability of AFM13 to engage innate immunity …
and activates NK cells. This study evaluates the ability of AFM13 to engage innate immunity …
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
U Reusch, C Burkhardt, I Fucek, F Le Gall, M Le Gall… - MAbs, 2014 - Taylor & Francis
… , we constructed a tetravalent bispecific CD30/CD16A tandem … TandAb were compared with
antibodies with identical anti-… , and (3) a bivalent bispecific CD30/CD16A diabody. Due to its …
antibodies with identical anti-… , and (3) a bivalent bispecific CD30/CD16A diabody. Due to its …
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
A Rothe, S Sasse, MS Topp… - Blood, The Journal …, 2015 - ashpublications.org
… AFM13 is a novel NK-cell–recruiting antibody that targets … The tetravalent bispecific TandAb
AFM13 seems to have a … bivalent, bispecific antibodies such as the BiTE antibodies, which …
AFM13 seems to have a … bivalent, bispecific antibodies such as the BiTE antibodies, which …
[HTML][HTML] A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide
… In this context, the objective of this study was to examine the physicochemical properties
and biological activities of a tetravalent bispecific immune cell engager and demonstrate its …
and biological activities of a tetravalent bispecific immune cell engager and demonstrate its …
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
T Gantke, M Weichel, C Herbrecht… - Protein Engineering …, 2017 - academic.oup.com
… In this study, we describe the development of a novel trispecific antibody … -class tetravalent
CD30/CD16A-directed bispecific tandem diabody (TandAb), AFM13, currently in active clinical …
CD30/CD16A-directed bispecific tandem diabody (TandAb), AFM13, currently in active clinical …
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma
S Kakiuchi-Kiyota, T Ross, HA Wallweber, JR Kiefer… - Leukemia, 2022 - nature.com
… ) AFM13 is a bispecific, tetravalent antibody that binds CD30, … profile of RO7297089 a novel
bispecific ICE® targeting BCMA … clinical proof of concept of the anti-CD30/CD16A bispecific …
bispecific ICE® targeting BCMA … clinical proof of concept of the anti-CD30/CD16A bispecific …
Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies
A Tapia-Galisteo, L Álvarez-Vallina, L Sanz - Journal of Hematology & …, 2023 - Springer
… review, we will discuss antibody formats, immunologic background, mechanisms of action,
relevant clinical … A detailed account of the clinical data and side effects would go beyond the …
relevant clinical … A detailed account of the clinical data and side effects would go beyond the …
First-in-Human Phase 1 study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors
A El-Khoueiry, O Saavedra, J Thomas… - Clinical Cancer …, 2025 - aacrjournals.org
… AFM24 is a novel, tetravalent bispecific EGFR/CD16A-targeting ICE® designed for the …
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients …
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients …
Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy
… combination therapy with other antibody drugs such as checkpoint inhibitors and antibody-drug
conjugates. Taken together, the data demonstrate the creation of a novel BiKE with high …
conjugates. Taken together, the data demonstrate the creation of a novel BiKE with high …